Welcome to our dedicated page for ZeroStack SEC filings (Ticker: ZSTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ZeroStack's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ZeroStack's regulatory disclosures and financial reporting.
Michael Heinrich filed an amended ownership report for ZeroStack Corp., showing beneficial ownership of 471,208 common shares, equal to 10.0% of the outstanding common shares. He holds sole voting and dispositive power over these shares.
A related entity, Zero Gravity Labs Inc., now reports ownership of 0 shares of ZeroStack. On March 31, 2026, ZeroStack entered into a Note Settlement Agreement with Zero Gravity Labs under which payment of 50,000,000 Tokens fully satisfied the principal and interest of a prior convertible promissory note, eliminating further obligations under that note.
ZeroStack Corp. Executive Chairman Heinrich Michael reported an "other" restructuring transaction involving a convertible promissory note held indirectly through Zero Gravity Labs Inc., a corporation he owns and controls. The note was tied to 4,902,220 common shares at a conversion price of $33.34 per share and had an expiration date in September 2035. A note settlement agreement provides that payment of 50,000,000 Tokens to Zero Gravity Labs Inc. fully satisfies the principal and interest, leaving no further obligations under the note and no remaining derivative holdings from this instrument.
ZeroStack Corp. entered into a series of agreements tied to its Zero Gravity (0G) token holdings and a planned share exchange. Texas Blocker Corp., formed by ZeroStack’s CEO and CFO, received 142,232,948 0G Tokens from investors in return for 9,104,614 Texas Blocker common shares, valued at US$0.7549 per Token and US$11.7931 per Blocker Share.
ZeroStack then signed a Share Exchange Agreement to issue 9,104,614 ZeroStack common shares and/or pre-funded warrants in exchange for all outstanding Texas Blocker shares, after required shareholder approvals. On closing, Texas Blocker will become a wholly owned subsidiary and ZeroStack expects to be treated as a U.S. domestic corporation for federal tax purposes under Section 7874(b).
Separately, ZeroStack agreed to settle a prior token-denominated convertible note by delivering 50,000,000 Tokens to Zero Gravity Labs Inc., fully satisfying principal and interest and providing mutual releases. The ZeroStack securities are being issued in an exempt, unregistered private offering framework.
ZeroStack Corp., formerly Flora Growth, files its annual report describing a major pivot from legacy hemp and cannabis into a combination of decentralized AI-focused digital asset treasury management and global pharmaceutical distribution through its German unit Phatebo.
The company is building a treasury concentrated in 0G Tokens and other cryptocurrencies, funded by multiple 2025 private placements that raised about $14.6M in cash plus significant token consideration, and by borrowing 50,000,000 0G Tokens under a convertible note with related party Zero Gravity Labs. It also issued and settled a Solana-denominated convertible note and entered a large token-funded pre-funded warrant deal.
ZeroStack sold its legacy hemp and cannabis subsidiaries in 2025 to extinguish promissory note obligations and now focuses on AI-linked digital assets and pharmaceutical wholesaling. Despite this repositioning, it remains early stage and deeply loss-making, with a $119.7M net loss in 2025 and an accumulated deficit of $277.8M. As of February 23, 2026, it had 2,430,808 common shares outstanding and a small workforce of 21 employees.